CLINIGEN Board Appointment

Clinigen Group plc (AIM: CLIN, “Clinigen” or the “Group”), the global pharmaceutical and services company, announces that Professor Alan Boyd has been appointed as a Non-Executive Director with immediate effect.

Alan is CEO of Boyd Consultants, a UK based consultancy to the pharmaceutical and biotechnology industry. He has over 30 years of sector experience, holding senior roles within Glaxo Group, ICI Pharma, Zeneca Pharmaceuticals and Ark Therapeutics. Alan is a graduate in Biochemistry and Medicine from the University of Birmingham and is currently a Fellow and immediate past President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians. He is also a Fellow of the Royal College of Physicians, London and a Council Member of the Academy of Medical Royal Colleges.

Alan is currently working as a consultant for Clinigen providing clinical and regulatory consultancy services in relation to its medical products.

Peter Allen, Chairman of Clinigen, said:

"On behalf of the Board, we are delighted to welcome Alan to the Group. He brings extensive industry experience and expertise in pharmaceutical services. His appointment strengthens the Board and will help to support and deliver the Group’s strategy. We are very much looking forward to working with Alan in his new NED capacity.”

The following information is disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Professor Alan Keith Boyd, aged 63 years, is currently or has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

• The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, UK
• BaxterBoyd Limited
• Celentyx Limited
• Alan Boyd Consultants Limited
• Basildon Court Residents Company Limited

Past directorships (last 5 years)

• Linear Diagnostics Limited
• Alta Bioscience Limited
• Bioscience Ventures Limited
• The Academy Of Medical Royal Colleges
• Genable Technologies Limited

There is no further information to be disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

- ENDS -

For further information please contact:

Clinigen Group plc
Peter Allen, Chairman
Shaun Chilton, Group Chief Executive Officer
Matt Parrish, Head of Investor Relations

Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas

Instinctif Partners
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell

Tel: +44 (0) 1283 495010

Tel: +44 (0) 20 7260 1000

 

Tel: +44 (0) 20 7653 4000

Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com